March 31, 2015

Amneal Pharmaceuticals will acquire Actavis Australia's generic pharmaceutical business. Financial terms of the agreement were not disclosed. 

March 24, 2015

Actavis last week announced that its acquisition of Allergan has been completed in a transaction valued at $70.5 billion, a deal that creates one of the world’s top 10 pharmaceutical companies by sales revenue, according to the company.

March 10, 2015

Actavis expanded its portfolio of topicals with the launch of a generic corticosteroid.

February 20, 2015

Actavis on Friday gained approval for a generic version of Reckitt Benckiser's Subutex, indicated for the treatment of opioid dependence.

February 18, 2015

Actavis on Wednesday announced that it will adopt a new corporate name — Allergan — following the anticipated, successful completion of the acquisition of Allergan.

January 27, 2015

Actavis on Monday agreed to acquire Auden Mckenzie Holdings for approximately $465.8 million in cash, plus a two-year royalty on a percentage of gross profits of one of Auden Mckenzie's products.

January 13, 2015

Actavis on Tuesday announced the launch of a leading portfolio of generic specialty injectable medications to be marketed to hospitals across the United States.

December 23, 2014

Specialty pharmaceutical company Actavis has hired Jonathon Kellerman as EVP, global chief compliance officer.

December 16, 2014

Actavis on Tuesday announced the planned senior management team that will lead the global pharmaceutical company following the successful close of the acquisition of Allergan.

November 17, 2014

Actavis will acquire Allergan for a combination of $129.22 in cash and 0.3683 Actavis shares for each share of Allergan common stock, the company announced Monday.

October 23, 2014

Actavis on Thursday confirmed that the United States Court of Appeals for the Federal Circuit has upheld a lower court ruling that found United States Patent No. 7,704,984 (the '984 Patent) to be valid.

October 7, 2014

Actavis and Durata Therapeutics on Monday announced that they have entered into a definitive merger agreement.

September 26, 2014

Actavis on Friday confirmed that it has filed an abbreviated new drug application with the Food and Drug Administration to market buprenorphine transdermal system, a generic version of Butrans from Purdue Pharma. 

July 3, 2014

Impax Labs on Wednesday announced that it has acquired from Actavis two generic products for cash consideration. Financial terms of the agreement were not disclosed.

July 2, 2014

Actavis on Wednesday announced that its subsidiary Forest Labs has successfully completed its acquisition of Furiex Pharmaceuticals in an all-cash transaction valued at approximately $1.1 billion, and up to approximately $360 million in a Contingent Value Right that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug, following approval.

July 1, 2014

Actavis and Forest Labs. on Monday announced that the U.S. Federal Trade Commission has voted to approve Actavis' proposed acquisition of Forest.

June 30, 2014

Actavis on Monday confirmed that it has filed an abbreviated new drug application with the Food and Drug Administration to market buprenorphine hydrochloride and naloxone hydrochloride dihydrate sublingual tablets.

June 19, 2014

Actavis confirmed that the U.S. District Court for the District of Delaware found certain claims of U.S. Patent Nos. 6,335,031 and 6,316,023 valid and infringed by the company's rivastigmine transdermal system, a generic version of Exelon Patch from Novartis.

June 17, 2014

Teva has reached settlements with Sandoz, Actavis, Lupin and Apotex with respect to a patent for Teva’s wakefulness product, Nuvigil (armodafinil) tablets.

June 3, 2014

Actavis last week announced that it has reached an agreement with Cephalon to settle all outstanding patent litigation associated with Actavis' generic version of Nuvigil (armodafinil tablets).

May 29, 2014

Gov. Alejandro García Padilla on Wednesday announced an agreement by Puerto Rico Industrial Development Co. with Actavis that will allow the pharmaceutical manufacturer to develop a solid dosage manufacturing and packing facility in its Manati site and expand its current hormone production in Fajardo.

May 28, 2014

Actavis on Tuesday confirmed that it has filed an abbreviated new drug application with the Food and Drug Administration seeking approval to market saxagliptin hydrochloride tablets, 2.5 mg and 5 mg.

May 15, 2014

Actavis has reached an agreement with Janssen Pharmaceuticals to continue supplying the authorized generic version of Janssen's Concerta (methylphenidate hydrochloride extended-release tablets), the company announced.

May 14, 2014

Actavis on Tuesday announced that it has received final approval from the Food and Drug Administration on its abbreviated new drug application for a generic version of Mallinckrodt's Exalgo (hydromorphone hydrochloride extended-release tablets 8 mg, 12 mg and 16 mg).